Olema Pharmaceuticals News

Olema Oncology to Participate in Upcoming Investor Conferences in June

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and

GlobeNewswireMay 28 19:03

Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans

Yahoo FinanceMay 24 20:08

Buy Rating Affirmed for Olema Pharmaceuticals on Strong Clinical Trial Data for Palazestrant and Ribociclib Combination

TipRanksMay 16 18:08

Buy Rating Justified by Promising Efficacy and Safety Profile of Olema Pharmaceuticals' Drug Combination in Clinical Studies

TipRanksMay 16 03:45

HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $30 price target.

BenzingaMay 16 01:58

Promising Clinical Trial Results Bolster Buy Rating for Olema Pharmaceuticals

TipRanksMay 15 23:45

OPEN, BCRX and AWIN Among Pre-market Gainers

Seeking AlphaMay 15 21:25

Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results

TipRanksMay 15 19:22

Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients

Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients

BenzingaMay 15 19:12

Olema Oncology Announces Promising New Data for Palazestrant in Combination With Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either

GlobeNewswireMay 15 19:01

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares

Simply Wall StMay 11 22:44

Olema Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Olema Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 10 03:41

HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $28

HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target from $25 to $28.

BenzingaMay 10 03:31

Olema Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 172.9% HC Wainwright & Co. $25 → $28 Maintains Buy 04/02/2024 133.92% Goldman Sachs → $24 Initi

BenzingaMay 10 03:30

Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)

TipRanksMay 9 20:04

Buy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial Position

TipRanksMay 9 19:05

Buy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis Collaboration

TipRanksMay 9 06:45

Olema Pharmaceuticals Q1 EPS $(0.56) Misses $(0.51) Estimate

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 20 percent increase over losses of $

BenzingaMay 9 05:05

Olema Pharmaceuticals | 10-Q: Quarterly report

SEC announcementMay 9 04:23 · Announcements

Olema Pharmaceuticals Cash, Cash Equivalents and Marketable Securities as of March 31 Were $249M >OLMA

Olema Pharmaceuticals Cash, Cash Equivalents and Marketable Securities as of March 31 Were $249M >OLMA

Dow JonesMay 9 04:12